RHAPSODY
2021
Rilonacept Inhibition of Interleukin-1 Alpha and Beta for Recurrent Pericarditis
In 86 patients with recurrent pericarditis and an elevated C-reactive protein level, continued weekly rilonacept prolonged time to first pericarditis recurrence compared with randomised withdrawal to placebo.
Result
Efficacy: Time to first adjudicated pericarditis recurrenceHR 0.04 (95% CI 0.01-0.18) · P < 0.001
Below 1 favours continued weekly rilonacept, above 1 favours randomised withdrawal to placebo.
- Absolute difference
- 67 points
- NNT
- 2
Absolute difference and NNT are derived from the event rates.
Also reported: Median time to recurrence 8.6 weeks on placebo, not reached with rilonacept.
- Subtopic
- Recurrent pericarditis
- Design
- Phase-3 double-blind randomised-withdrawal RCT (86 enrolled in run-in, 61 randomised)
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2025 Myo/Pericarditis
- Source
- Klein AL, Imazio M, Cremer P, et al. N Engl J Med. 2021;384(1):31-41.doi 10.1056/NEJMoa2027892
Discussion & critique
Only run-in responders were randomised and the placebo arm was abruptly de-escalated from an effective drug, which exaggerates the contrast; there is no active comparator and no stopping-rule data. It is still the largest and methodologically strongest trial ever done in recurrent pericarditis.